Rapamycin increases leukemia cell sensitivity to chemotherapy by regulating mTORC1 pathway-mediated apoptosis and autophagy
International Journal of Hematology · 2024
DOI: 10.1007/s12185-024-03732-0 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Hematology, 2024. Verfasst von Jing Xu und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, The Second Affiliated Hospital of Nanchang University, No. 1 Minde Road, Nanchang, 330006, China. Hauptthemen laut MEDLINE: Autophagy, Apoptosis, Mechanistic Target of Rapamycin Complex 1, Sirolimus. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 38 Literaturangaben. Gefördert von: the National Natural Science Foundation of China, Jiangxi "5511" Science and Technology Innovation Talent Project.
Themen: Onkologische Pflege
Abstract (Originalsprache)
This study investigated the effect of rapamycin alone and in combination with chemotherapy (doxorubicin and cytarabine) on AML. Human acute monocytic leukemia cell line SHI-1 and NPG AML model mice created by intravenous injection of SHI-1 cell were treated with rapamycin, chemotherapy, or rapamycin plus chemotherapy. Analysis by cell counting kit-8, western blot, flow cytometry, and immunohistochemistry was performed, and results suggested that both rapamycin and chemotherapy inhibited proliferation of SHI-1 cells both in vitro and in vivo, suppressed neoplasm growth in vivo, and promoted survival of NPG AML mice. The antitumor effect of rapamycin plus chemotherapy was better than that of rapamycin alone and chemotherapy alone. In addition, western blot results demonstrated that rapamycin inhibited the phosphorylation of mTOR downstream targets 4EBP1 and S6K1 in SHI-1 cells, and increased the pro-apoptosis-related protein Bax and autophagy-associated proteins Beclin-1, LC3B-II, and ATG5 while reducing the anti-apoptosis-related protein Bcl-2. In conclusion, the results of this study indicate that rapamycin acts synergistically with doxorubicin and cytarabine in AML treatment, and its underlying mechanism might be associated with mTORC1 pathway-mediated apoptosis and autophagy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Hematology, The Second Affiliated Hospital of Nanchang University, No. 1 Minde Road, Nanchang, 330006, China.
- Second Clinical Medical College, Nanchang University, Nanchang, 330006, China.
- Department of Clinical Laboratory, The Second Affiliated Hospital of Nanchang University, Nanchang, 330006, China.
- Department of Hematology, The Second Affiliated Hospital of Nanchang University, No. 1 Minde Road, Nanchang, 330006, China. lzjdgh@163.com.
Förderung
- the National Natural Science Foundation of China
- Jiangxi "5511" Science and Technology Innovation Talent Project
Zitieren
APA
Xu, J., Zong, S., Sheng, T., Zheng, J., Wu, Q., Wang, Q., Tang, A., Song, Y., Fei, Y., & Li, Z. (2024). Rapamycin increases leukemia cell sensitivity to chemotherapy by regulating mTORC1 pathway-mediated apoptosis and autophagy. International Journal of Hematology. https://doi.org/10.1007/s12185-024-03732-0
Vancouver
Xu J, Zong S, Sheng T, Zheng J, Wu Q, Wang Q, et al. Rapamycin increases leukemia cell sensitivity to chemotherapy by regulating mTORC1 pathway-mediated apoptosis and autophagy. International Journal of Hematology. 2024. doi:10.1007/s12185-024-03732-0
BibTeX
@article{Xu2024,
author = {Xu, Jing and Zong, Siwen and Sheng, Tianle and Zheng, Jifu and Wu, Qiong and Wang, Qingming and Tang, Aiping and Song, Yuan and Fei, Yan and Li, Zhenjiang},
title = {Rapamycin increases leukemia cell sensitivity to chemotherapy by regulating mTORC1 pathway-mediated apoptosis and autophagy},
journal = {International Journal of Hematology},
year = {2024},
doi = {10.1007/s12185-024-03732-0}
}
EUVIMED